The L3MBTL3 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population harboring gene-disrupting mutations at the L3MBTL3 locus, creating a functional knockout model devoid of wild-type protein expression. This heterogeneous pool circumvents clonal selection, maintaining genetic diversity while enabling robust loss-of-function studies in a cancer-relevant cellular background. The inactivation of L3MBTL3 permits systematic dissection of its roles in chromatin-mediated gene silencing and epigenetic regulation, providing a valuable tool for researchers in epigenetics and oncology.
HeLa cells, an HPV-18-positive cervical adenocarcinoma line, feature epithelial morphology and constitutive inactivation of p53 and Rb by viral oncoproteins. This immortalized line is a workhorse in cancer research, prized for its reproducible growth and amenability to genetic manipulation. The compromised p53 and Rb checkpoints in HeLa cells create a sensitized genetic environment, making them particularly suitable for interrogating additional chromatin-level regulators like L3MBTL3 that may function in tumor suppression.
L3MBTL3 is a methyl-lysine reader that specifically binds H4K20me1/2 and H3K9me1/2, directing the assembly of corepressor complexes and chromatin compaction at target gene promoters. These histone modifications are deposited by upstream methyltransferases SUV420H1, SUV420H2, and SETDB1, establishing a signaling cascade that culminates in L3MBTL3-dependent transcriptional repression of key downstream networks, including E2F- and MYC-regulated genes and cell cycle regulators. The knockout of L3MBTL3 disrupts this repressive mechanism, potentially leading to aberrant reactivation of oncogenic programs and altered chromatin architecture.
Given that L3MBTL3 maps to the commonly deleted 20q region in myeloid malignancies and certain solid tumors, its deletion in the HeLa background models loss-of-function events relevant to cancer epigenetics. The concurrent HPV-driven inactivation of p53 and Rb may synergize with L3MBTL3 deficiency to further deregulate transcriptional programs, offering a unique platform to investigate the interplay between viral transformation and histone modification-dependent tumor suppression. This model thus enables the exploration of L3MBTL3 as a context-dependent epigenetic barrier.
This product is optimized for functional epigenomics, with applications including ChIP-qPCR to map histone modification changes, RNA-seq and ATAC-seq for transcriptomic and chromatin accessibility profiling, and Western blotting/RT-qPCR to confirm knockout and pathway alterations. Phenotypic assays such as proliferation and colony formation quantify tumor-suppressive activity, while complementation studies with wild-type or mutant L3MBTL3 facilitate mechanistic dissection. For further technical details or to inquire about custom knockout services, please contact Ascent Research.
